ImmunoCellular Therapeutics Ltd. | |
Stock Exchange | NYSE |
EPS |
$0.47 |
Market Cap |
$784.05 K |
Shares Outstanding |
41.93 M |
Public Float |
41.75 M |
Address |
30721 Russell Ranch Road Westlake Village California 91362 United States |
Employees | - |
Website | http://www.imuc.com |
Updated | 07/08/2019 |
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. |